Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep;102(9):1558–1566. doi: 10.3324/haematol.2017.164046

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2017 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 4. — In vivo environment affects the oncogenic transformation of primary human hematopoietic stem and progenitor cells by t(11;19) (A) Survival of serially transplanted mice with human cell engraftment. Donor: primary recipients with [L-CRISPR-CTN(11;19)] a monocytic leukemia-like disease (Mono #1/#2), a healthy mouse with a detectable MLL-ENL breakpoint but no disease in the primary recipient, and two control donors (MLL-I9-#1 + Luc sgRNAs) (n = 3 per donor). (B) Analysis of bone marrow (BM) cell morphology (left: MGG, 1000x) and liver histopathology (right: HE, 100X) showing severe infiltration of a secondary recipient transplanted with monocytic leukemia-like disease cells. (C) Flow cytometry analysis of monocytic leukemia cells for monocytic and progenitor cell surface marker expression. (D) Flow cytometry analysis of B-ALL cells. (E) Analysis of BM cell morphology (MGG, 1000x) of a secondary recipient with B-ALL. (F) Detection of an MLL translocation with fluorescence in situ hybridization on interphase nuclei of B-ALL cells (Vysis LSI MLL probe; Abbott Laboratories). (G) Alignment of Sanger sequencing-derived genomic t(11;19)/MLL-ENL breakpoints of mice with B-ALL (Secondary) compared to the healthy primary (Primary) mouse.